Wu J - Search Results

1

PTPN11 Plays Oncogenic Roles and Is a Therapeutic Target for BRAF Wild-Type Melanomas.

Hill KS, Roberts ER, Wang X, Marin E, Park TD, Son S, Ren Y, Fang B, Yoder S, Kim S, Wan L, Sarnaik AA, Koomen JM, Messina JL, Teer JK, Kim Y, Wu J, Chalfant CE, Kim M. Hill KS, et al. Among authors: wu j. Mol Cancer Res. 2019 Feb;17(2):583-593. doi: 10.1158/1541-7786.MCR-18-0777. Epub 2018 Oct 24. Mol Cancer Res. 2019. PMID: 30355677 Free PMC article.

2

Selective inhibition of leukemia-associated SHP2^E69K mutant by the allosteric SHP2 inhibitor SHP099.

Sun X, Ren Y, Gunawan S, Teng P, Chen Z, Lawrence HR, Cai J, Lawrence NJ, Wu J. Sun X, et al. Among authors: wu j. Leukemia. 2018 May;32(5):1246-1249. doi: 10.1038/s41375-018-0020-5. Epub 2018 Jan 30. Leukemia. 2018. PMID: 29568093 Free PMC article. No abstract available.

3

RETooling the RET Inhibitor Pralsetinib for ESR1 Fusion-Positive Breast Cancer and Beyond.

Wu J, Subbiah V. Wu J, et al. Cancer Res. 2023 Oct 2;83(19):3159-3161. doi: 10.1158/0008-5472.CAN-23-1021. Cancer Res. 2023. PMID: 37779428

4

Activation of extracellular signal-regulated kinase (ERK) by mitogenic stimuli is repressed in v-Src-transformed cells.

Stofega MR, Yu CL, Wu J, Jove R. Stofega MR, et al. Among authors: wu j. Cell Growth Differ. 1997 Jan;8(1):113-9. Cell Growth Differ. 1997. PMID: 8993840

5

Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein.

Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, Frank DA, Holzman LB, Wu J, Sebti S, Jove R. Turkson J, et al. Among authors: wu j. Mol Cell Biol. 1999 Nov;19(11):7519-28. doi: 10.1128/MCB.19.11.7519. Mol Cell Biol. 1999. PMID: 10523640 Free PMC article.

6

Requirement of SHP2 binding to Grb2-associated binder-1 for mitogen-activated protein kinase activation in response to lysophosphatidic acid and epidermal growth factor.

Cunnick JM, Dorsey JF, Munoz-Antonia T, Mei L, Wu J. Cunnick JM, et al. Among authors: wu j. J Biol Chem. 2000 May 5;275(18):13842-8. doi: 10.1074/jbc.275.18.13842. J Biol Chem. 2000. PMID: 10788507 Free article.

7

The pyrido[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells.

Dorsey JF, Jove R, Kraker AJ, Wu J. Dorsey JF, et al. Among authors: wu j. Cancer Res. 2000 Jun 15;60(12):3127-31. Cancer Res. 2000. PMID: 10866298

8

Phosphotyrosines 627 and 659 of Gab1 constitute a bisphosphoryl tyrosine-based activation motif (BTAM) conferring binding and activation of SHP2.

Cunnick JM, Mei L, Doupnik CA, Wu J. Cunnick JM, et al. Among authors: wu j. J Biol Chem. 2001 Jun 29;276(26):24380-7. doi: 10.1074/jbc.M010275200. Epub 2001 Apr 25. J Biol Chem. 2001. PMID: 11323411 Free article.

9

Reversible regulation of SHP-1 tyrosine phosphatase activity by oxidation.

Cunnick JM, Dorsey JF, Mei L, Wu J. Cunnick JM, et al. Among authors: wu j. Biochem Mol Biol Int. 1998 Aug;45(5):887-94. doi: 10.1002/iub.7510450506. Biochem Mol Biol Int. 1998. PMID: 9739453

10

Drug resistance profiles of mutations in the RET kinase domain.

Liu X, Shen T, Mooers BHM, Hilberg F, Wu J. Liu X, et al. Among authors: wu j. Br J Pharmacol. 2018 Sep;175(17):3504-3515. doi: 10.1111/bph.14395. Epub 2018 Jul 19. Br J Pharmacol. 2018. PMID: 29908090 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

72,303 results

Search Page